Clinical burden of obstructive hypertrophic cardiomyopathy in France
Patients with obstructive HCM are at high risk of death and cardiovascular outcomes, especially those in higher NYHA classes. Despite current therapeutics, the clinical burden of symptomatic obstructive HCM remains high, supporting the need for additional therapies.
Authors
- Philippe Charron (ORCID: https://orcid.org/0000-0002-1782-1118)
- Jean‐Noël Trochu (ORCID: https://orcid.org/0000-0003-4742-281X)
- Carla Zema
- François-Emery Cotté (ORCID: https://orcid.org/0000-0002-6758-4552)
- F. Daydé (ORCID: https://orcid.org/0000-0002-9805-5864)
- É. Herquelot
- Taryn Krause (ORCID: https://orcid.org/0009-0009-5681-8497)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Sorbonne Université (FR)
- Bristol-Myers Squibb (United States) (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Bristol-Myers Squibb (France) (FR)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Institut du Thorax (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-01-22
- DOI
- https://doi.org/10.3389/fcvm.2024.1458410
- Citations
- 1
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39